NG2 cell response in the CNP-EGFP mouse after contusive spinal cord injury.

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8806785 Publication Model: Print Cited Medium: Internet ISSN: 1098-1136 (Electronic) Linking ISSN: 08941491 NLM ISO Abbreviation: Glia Subsets: MEDLINE

Publication: New York, NY : Wiley-Liss
Original Publication: New York : Alan R. Liss, Inc., c1988-

Adult Stem Cells/*physiology ; Oligodendroglia/*physiology ; Spinal Cord Injuries/*pathology ; Spinal Cord Injuries/*physiopathology; Action Potentials/drug effects ; Action Potentials/genetics ; Adult Stem Cells/drug effects ; Animals ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; Behavior, Animal ; Bromodeoxyuridine/metabolism ; Cell Proliferation/drug effects ; Cyclic Nucleotide Phosphodiesterases, Type 3/genetics ; Disease Models, Animal ; Fibroblast Growth Factor 2/pharmacology ; Gene Expression Regulation/genetics ; Gene Expression Regulation/physiology ; Green Fluorescent Proteins/genetics ; HMGB Proteins/metabolism ; Mice ; Mice, Transgenic ; Nerve Tissue Proteins/genetics ; Nerve Tissue Proteins/metabolism ; Nerve Tissue Proteins/pharmacology ; Neuregulin-1 ; Oligodendrocyte Transcription Factor 2 ; Oligodendroglia/drug effects ; Potassium Channels, Voltage-Gated/metabolism ; SOXE Transcription Factors/metabolism ; SOXF Transcription Factors/metabolism ; Spinal Cord Injuries/drug therapy ; Time Factors

NG2(+) cells in the adult CNS are a heterogeneous population. The extent to which the subpopulation of NG2(+) cells that function as oligodendrocyte progenitor cells (OPCs) respond to spinal cord injury (SCI) and recapitulate their normal developmental progression remains unclear. We used the CNP-EGFP mouse, in which oligodendrocyte lineage cells express EGFP, to study NG2(+) cells in the normal and injured spinal cord. In white matter of uninjured mice, bipolar EGFP(+)NG2(+) cells and multipolar EGFP(neg)NG2(+) cells were identified. After SCI, EGFP(+)NG2(+) cell proliferation in residual white matter peaked at 3 days post injury (DPI) rostral to the epicenter, while EGFP(neg)NG2(+) cell proliferation peaked at 7 DPI at the epicenter. The expression of transcription factors, Olig2, Sox10, and Sox17, and the basic electrophysiological membrane parameters and potassium current phenotype of the EGFP(+)NG2(+) population after injury were consistent with those of proliferative OPCs during development. EGFP(neg)NG2(+) cells did not express transcription factors involved in oligodendrogenesis. EGFP(+)CC1(+) oligodendrocytes at 6 weeks included cells that incorporated BrdU during the peak of EGFP(+)NG2(+) cell proliferation. EGFP(neg)CC1(+) oligodendrocytes were never observed. Treatment with glial growth factor 2 and fibroblast growth factor 2 enhanced oligodendrogenesis and increased the number of EGFP(neg)NG2(+) cells. Therefore, based on EGFP and transcription factor expression, spatiotemporal proliferation patterns, and response to growth factors, two populations of NG2(+) cells can be identified that react to SCI. The EGFP(+)NG2(+) cells undergo cellular and physiological changes in response to SCI that are similar to those that occur in early postnatal NG2(+) cells during developmental oligodendrogenesis.

Glia. 2001 May;34(3):213-28. (PMID: 11329183)
Nature. 1983 Jun 2-8;303(5916):390-6. (PMID: 6304520)
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7853-8. (PMID: 16682644)
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2350-5. (PMID: 11854528)
J Comp Neurol. 2003 Jul 21;462(2):223-40. (PMID: 12794745)
J Neurosci. 2002 Apr 1;22(7):2792-803. (PMID: 11923444)
Glia. 2002 Oct;40(1):25-43. (PMID: 12237841)
J Cell Biol. 2003 Apr 14;161(1):169-86. (PMID: 12682089)
Neuron. 1994 Jun;12(6):1353-62. (PMID: 7516688)
Brain Res. 2005 Aug 9;1052(2):147-55. (PMID: 16005441)
Glia. 2007 May;55(7):698-711. (PMID: 17330874)
J Neurosci. 1998 Nov 1;18(21):8780-93. (PMID: 9786985)
J Neurosci. 1996 Apr 15;16(8):2659-70. (PMID: 8786442)
Exp Neurol. 2001 Apr;168(2):273-82. (PMID: 11259115)
Glia. 2005 Feb;49(3):318-38. (PMID: 15494983)
Mol Cell Neurosci. 2004 Dec;27(4):453-65. (PMID: 15555923)
Dev Biol. 2007 Feb 15;302(2):683-93. (PMID: 17098222)
Development. 1999 Feb;126(5):1077-90. (PMID: 9927607)
J Neurosci. 1997 Apr 15;17(8):2669-82. (PMID: 9092588)
Neuroscience. 1994 Nov;63(1):135-49. (PMID: 7898644)
J Neurosci Res. 2002 Nov 15;70(4):529-45. (PMID: 12404507)
Development. 2007 Apr;134(8):1617-29. (PMID: 17344230)
J Physiol (Paris). 1987;82(4):327-35. (PMID: 2460620)
Brain. 2003 Jun;126(Pt 6):1382-91. (PMID: 12764059)
Glia. 2006 Jul;54(1):1-10. (PMID: 16652341)
J Neurosci. 1999 Jul 1;19(13):5380-92. (PMID: 10377348)
Cent Nerv Syst Trauma. 1985 Winter;2(4):299-315. (PMID: 3836014)
Nat Neurosci. 2001 Oct;4(10):973-4. (PMID: 11574831)
J Neurocytol. 2002 Jul-Aug;31(6-7):537-49. (PMID: 14501222)
Exp Neurol. 1973 Mar;38(3):472-87. (PMID: 4696114)
J Neurosci. 1997 Nov 1;17(21):8234-45. (PMID: 9334399)
Neurosurgery. 2002 May;50(5):1075-81; discussion 1081-2. (PMID: 11950411)
J Neurosci. 2001 Dec 15;21(24):9814-23. (PMID: 11739589)
J Comp Neurol. 2006 Oct 1;498(4):525-38. (PMID: 16874803)
Glia. 2005 Jan 1;49(1):107-20. (PMID: 15390101)
J Neurocytol. 2002 Jul-Aug;31(6-7):437-55. (PMID: 14501215)
J Anat. 2005 Dec;207(6):695-706. (PMID: 16367797)
Nature. 1993 Jan 21;361(6409):258-60. (PMID: 8093806)
Neuroscience. 1983 Dec;10(4):1471-86. (PMID: 6664497)
Adv Exp Med Biol. 1999;468:183-97. (PMID: 10635029)
Eur J Neurosci. 2007 Mar;25(6):1711-24. (PMID: 17432960)
Genes Dev. 2005 Jan 15;19(2):282-94. (PMID: 15655114)
Ann Neurol. 1984 Aug;16(2):216-21. (PMID: 6089647)
J Neurosci. 2002 Feb 1;22(3):876-85. (PMID: 11826117)
Neuron. 1990 Apr;4(4):507-24. (PMID: 1691005)
J Comp Neurol. 2006 Feb 1;494(4):578-94. (PMID: 16374800)
Perspect Dev Neurobiol. 1996;3(4):245-59. (PMID: 9117258)
Neuron. 1989 Feb;2(2):1135-45. (PMID: 2560386)
J Neurocytol. 2002 Jul-Aug;31(6-7):457-67. (PMID: 14501216)
Glia. 1993 Apr;7(4):307-21. (PMID: 8320001)
J Physiol. 2004 Nov 15;561(Pt 1):109-22. (PMID: 15358811)
Adv Neurol. 1997;72:335-45. (PMID: 8993710)
J Neurocytol. 2002 Jul-Aug;31(6-7):469-80. (PMID: 14501217)
Glia. 2007 Jun;55(8):831-43. (PMID: 17390308)
J Neurosci. 2006 Sep 20;26(38):9722-35. (PMID: 16988043)
Glia. 2005 Aug 1;51(2):81-97. (PMID: 15782413)
J Neurosci Res. 1997 Mar 1;47(5):455-70. (PMID: 9067855)
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18183-8. (PMID: 16330768)
Mol Cell Neurosci. 2003 Aug;23(4):544-58. (PMID: 12932436)
Glia. 2004 Dec;48(4):337-45. (PMID: 15390108)
Ann N Y Acad Sci. 1991;633:64-77. (PMID: 1724138)
Eur J Neurosci. 2003 Oct;18(8):2253-64. (PMID: 14622186)
J Neurotrauma. 2005 Jan;22(1):157-71. (PMID: 15665610)
Dev Biol. 1981 Apr 15;83(1):154-65. (PMID: 7016634)
Glia. 2004 Jan 1;45(1):1-16. (PMID: 14648541)
Exp Neurol. 2005 Mar;192(1):11-24. (PMID: 15698615)
J Neurotrauma. 2006 May;23(5):635-59. (PMID: 16689667)
J Neurosci. 2004 Nov 17;24(46):10530-41. (PMID: 15548668)
Exp Neurol. 2005 Nov;196(1):9-17. (PMID: 16023101)
Glia. 2001 Jun;34(4):296-310. (PMID: 11360302)
Trends Neurosci. 2001 Jan;24(1):39-47. (PMID: 11163886)
J Neurosci. 2006 Nov 15;26(46):11948-60. (PMID: 17108169)
J Neurosci. 2000 Mar 15;20(6):2218-28. (PMID: 10704497)
J Neurosci Res. 1996 Feb 01;43(3):299-314. (PMID: 8714519)
J Neurol. 1994 Dec;242(1 Suppl 1):S19-21. (PMID: 7699403)
Mol Cell Neurosci. 2004 Nov;27(3):247-54. (PMID: 15519240)
Neuroscience. 1983 Oct;10(2):521-43. (PMID: 6633870)
Nat Neurosci. 2005 Jul;8(7):865-72. (PMID: 15951811)
J Cell Biol. 2004 May 24;165(4):575-89. (PMID: 15159421)
Prog Neurobiol. 2002 Aug;67(6):451-67. (PMID: 12385864)
J Neurotrauma. 2006 Dec;23(12):1726-38. (PMID: 17184184)
Glia. 2005 May;50(3):247-57. (PMID: 15739189)
Perspect Dev Neurobiol. 1995;2(4):347-56. (PMID: 7538867)
J Neurosci. 1995 Jan;15(1 Pt 1):394-406. (PMID: 7823144)
J Neurosci. 2001 May 15;21(10):3392-400. (PMID: 11331369)
Dev Neurobiol. 2007 Jun;67(7):860-74. (PMID: 17506499)
Int J Dev Neurosci. 2001 Jul;19(4):379-85. (PMID: 11378298)
Cell Tissue Res. 2003 Feb;311(2):131-8. (PMID: 12596033)
J Neurocytol. 2002 Jul-Aug;31(6-7):551-65. (PMID: 14501223)
J Neurotrauma. 1998 Feb;15(2):125-40. (PMID: 9512088)
Nature. 1974 Jun 7;249(457):577-8. (PMID: 4834082)
J Neurocytol. 2002 Jul-Aug;31(6-7):423-35. (PMID: 14501214)
J Neurosci. 2005 Sep 21;25(38):8601-10. (PMID: 16177027)
J Neurosci. 2006 Jan 25;26(4):1275-80. (PMID: 16436615)
J Neurosci Res. 1995 Nov 1;42(4):579-93. (PMID: 8568944)

R01 NS045702-05 United States NS NINDS NIH HHS; R01-NS056427 United States NS NINDS NIH HHS; R01 NS035647 United States NS NINDS NIH HHS; 5F31NS051086-02 United States NS NINDS NIH HHS; R01-NS045702 United States NS NINDS NIH HHS; R01 NS045702 United States NS NINDS NIH HHS; R01 NS056427-03 United States NS NINDS NIH HHS; F31 NS051086 United States NS NINDS NIH HHS; R01 NS056427 United States NS NINDS NIH HHS; R01-NS035647 United States NS NINDS NIH HHS; R01 NS035647-10 United States NS NINDS NIH HHS

0 (Basic Helix-Loop-Helix Transcription Factors)
0 (HMGB Proteins)
0 (Nerve Tissue Proteins)
0 (Neuregulin-1)
0 (Nrg1 protein, mouse)
0 (Olig2 protein, mouse)
0 (Oligodendrocyte Transcription Factor 2)
0 (Potassium Channels, Voltage-Gated)
0 (SOXE Transcription Factors)
0 (SOXF Transcription Factors)
0 (Sox10 protein, mouse)
0 (Sox17 protein, mouse)
0 (enhanced green fluorescent protein)
103107-01-3 (Fibroblast Growth Factor 2)
147336-22-9 (Green Fluorescent Proteins)
EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
G34N38R2N1 (Bromodeoxyuridine)

Date Created: 20080830 Date Completed: 20090428 Latest Revision: 20211020

20221213

PMC2696059

10.1002/glia.20755

18756526